Combination of the CCL5-derived peptide R4.0 with different HIV-1 blockers reveals wide target compatibility and synergic cobinding to CCR5

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 6215-6223

  Secchi, Massimiliano ^a   Vassena, Lia ^a,d   Morin, Sébastien ^b,e   Schols, Dominique ^c   Vangelista, Luca ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF BASEL   (Switzerland)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^e UNAIDS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CCL5 DERIVED PEPTIDE R3.0; CCL5 DERIVED PEPTIDE R4.0; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; EMTRICITABINE; GLYCOPROTEIN GP 120; MARAVIROC; RANTES; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; PEPTIDE;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFECT; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; IC50; MOLECULAR DOCKING; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR BLOCKING; VIRUS INHIBITION; VIRUS STRAIN; WILD TYPE; BIOLOGICAL MODEL; CHEMISTRY; FLUORESCENCE MICROSCOPY;

ANTI-HIV AGENTS; MICROSCOPY, FLUORESCENCE; MODELS, BIOLOGICAL; PEPTIDES; RECEPTORS, CCR5;

EID: 84907270641     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03559-14     Document Type: Article

References (49)

1. UNAIDS. 2012. Together we will end AIDS, 2012. UNAIDS, Geneva, Switzerland. http://www.unaids.org/en/resources/campaigns/togetherwewillendaids.
2. Chun TW, Fauci AS. 2012. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 26:1261-1268. http://dx.doi.org/10.1097/QAD.0b013e328353f3f1.
3. Picker LJ, Hansen SG, Lifson JD. 2012. New paradigms for HIV/AIDS vaccine development. Annu. Rev. Med. 63:95-111. http://dx.doi.org/10 .1146/annurev-med-042010-085643.
4. Anonymous. 2014. HIV immunity goes direct. Nat. Biotechnol. 32:397. (Editorial.) http://dx.doi.org/10.1038/nbt.2907.
5. Kelly CG, Shattock RJ. 2011. Specific microbicides in the prevention of HIV infection. J. Intern. Med. 270:509-519. http://dx.doi.org/10.1111/j .1365-2796.2011.02454.x.
6. Goldberg DE, Siliciano RF, Jacobs WR, Jr. 2012. Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. Cell 148:1271-1283. http://dx.doi.org/10.1016/j.cell.2012.02.021.
7. Hladik F, McElrath MJ. 2008. Setting the stage: host invasion by HIV. Nat. Rev. Immunol. 8:447-457. http://dx.doi.org/10.1038/nri2302.
8. Wilkin TJ, Gulick RM. 2012. CCR5 antagonism in HIV infection: current concepts and future opportunities. Annu. Rev. Med. 63:81-93. http://dx .doi.org/10.1146/annurev-med-052010-145454.
9. Gaertner H, Cerini F, Escola JM, Kuenzi G, Melotti A, Offord R, Rossitto-Borlat I, Nedellec R, Salkowitz J, Gorochov G, Mosier D, Hartley O. 2008. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc. Natl. Acad. Sci. U. S. A. 105: 17706-17711. http://dx.doi.org/10.1073/pnas.0805098105.
10. Secchi M, Longhi R, Vassena L, Sironi F, Grzesiek S, Lusso P, Vangelista L. 2012. Enhancement of anti-HIV-1 activity by hot spot evolution of RANTES-derived peptides. Chem. Biol. 19:1579-1588. http://dx.doi.org/10.1016/j.chembiol.2012.10.007.
11. Vangelista L, Secchi M, Lusso P. 2008. Rational design of novel HIV-1 entry inhibitors by RANTES engineering. Vaccine 26:3008-3015. http://dx.doi.org/10.1016/j.vaccine.2007.12.023.
12. Nardese V, Longhi R, Polo S, Sironi F, Arcelloni C, Paroni R, DeSantis C, Sarmientos P, Rizzi M, Bolognesi M, Pavone V, Lusso P. 2001. Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES. Nat. Struct. Biol. 8:611-615. http://dx.doi.org/10.1038/89653.
13. Vangelista L, Longhi R, Sironi F, Pavone V, Lusso P. 2006. Critical role of the N-loop and beta1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity. Biochem. Biophys. Res. Commun. 351:664-668. http://dx.doi.org/10.1016/j.bbrc.2006.10.090.
14. Lusso P, Vangelista L, Cimbro R, Secchi M, Sironi F, Longhi R, Faiella M, Maglio O, Pavone V. 2011. Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity. FASEB J. 25:1230-1243. http://dx.doi.org/10.1096/fj.10-167627.
15. Nussbaum O, Broder CC, Berger EA. 1994. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J. Virol. 68:5411-5422.
16. Lusso P, Cocchi F, Balotta C, Markham PD, Louie A, Farci P, Pal R, Gallo RC, Reitz MS, Jr. 1995. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J. Virol. 69:3712-3720.
17. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55. http://dx.doi.org/10.1016/0065-2571(84)90007-4.
18. Chou TC. 1991. The median-effect principle and the combination index for quantization of synergism and antagonism, p 61-102. In Chou TC, Rideout DC (ed), Synergism and antagonism in chemotherapy. Academic Press, San Diego, CA.
19. Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, Gulakowski RJ, Wu L, Rivera MI, Laurencot CM, Currens MJ, Cardellina JH, II, Buckheit RW, Jr, Nara PL, Pannell LK, Sowder RC, II, Henderson LE. 1997. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob. Agents Chemother. 41:1521-1530.
20. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
21. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302-1307. http://dx.doi.org/10.1038/3293.
22. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F, Tauer C, Berger R, Barrett N, Jungbauer A, Katinger H. 1994. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 10:1651-1658. http://dx.doi.org/10.1089/aid.1994.10.1651.
23. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17:1757-1765. http://dx.doi .org/10.1089/08892220152741450.
24. Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Darke PL, Zugay J, Quintero JC, Blahy OM, Roth E, Sardana VV, Schlabach AJ, Graham PI, Condra JH, Gotlib L, Holloway MK, Lini J, Chen IW, Vastag K, Ostovic D, Anderson PS, Emini EA, Huff JR. 1994. L-735, 524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. U. S. A. 91:4096-4100. http://dx.doi.org/10.1073/pnas.91.9.4096.
25. Balzarini J, Holy A, Jindrich J, Naesens L, Snoeck R, Schols D, De Clercq E. 1993. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2- phosphonomethoxypropyl)-2, 6-diaminopurine. Antimicrob. Agents Chemother. 37:332-338. http://dx.doi.org/10.1128/AAC.37.2.332.
26. Schinazi RF, McMillan A, Cannon D, Mathis R, Lloyd RM, Peck A, Sommadossi JP, St Clair M, Wilson J, Furman PA, Painter G, Choi WB, Liotta DC. 1992. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1, 3- oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36:2423-2431. http://dx.doi.org/10.1128/AAC.36.11.2423.
27. Murga JD, Franti M, Pevear DC, Maddon PJ, Olson WC. 2006. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 50:3289-3296. http://dx.doi.org/10.1128/AAC.00699-06.
28. Escola JM, Kuenzi G, Gaertner H, Foti M, Hartley O. 2010. CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi network. J. Biol. Chem. 285:41772-41780. http://dx.doi .org/10.1074/jbc.M110.153460.
29. De Clercq E. 2013. The acyclic nucleoside phosphonates (ANPs): Antonín Holý's legacy. Med. Res. Rev. http://dx.doi.org/10.1002/med.21283.
30. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81:2359-2371. http://dx.doi.org/10.1128/JVI.02006-06.
31. Ogert RA, Ba L, Hou Y, Buontempo C, Qiu P, Duca J, Murgolo N, Buontempo P, Ralston R, Howe JA. 2009. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc. J. Virol. 83:12151-12163. http://dx.doi.org/10.1128/JVI.01351-09.
32. Roche M, Jakobsen MR, Sterjovski J, Ellett A, Posta F, Lee B, Jubb B, Westby M, Lewin SR, Ramsland PA, Churchill MJ, Gorry PR. 2011. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J. Virol. 85:4330-4342. http://dx.doi.org/10.1128/JVI.00106-11.
33. Roche M, Salimi H, Duncan R, Wilkinson BL, Chikere K, Moore MS, Webb NE, Zappi H, Sterjovski J, Flynn JK, Ellett A, Gray LR, Lee B, Jubb B, Westby M, Ramsland PA, Lewin SR, Payne RJ, Churchill MJ, Gorry PR. 2013. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology 10:43. http://dx.doi .org/10.1186/1742-4690-10-43.
34. Margolis L, Shattock R. 2006. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat. Rev. Microbiol. 4:312-317. http://dx.doi.org/10.1038/nrmicro1387.
35. Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, McElrath MJ. 2007. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26: 257-270. http://dx.doi.org/10.1016/j.immuni.2007.01.007.
36. Shen R, Richter HE, Clements RH, Novak L, Huff K, Bimczok D, Sankaran-Walters S, Dandekar S, Clapham PR, Smythies LE, Smith PD. 2009. Macrophages in vaginal but not intestinal mucosa are monocytelike and permissive to human immunodeficiency virus type-1 infection. J. Virol. 83:3258-3267. http://dx.doi.org/10.1128/JVI.01796-08.
37. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. 1995. Identification of RANTES, MIP-1, and MIP-1α as the major HIVsuppressive factors produced by CD8β T cells. Science 270:1811-1815. http://dx.doi.org/10.1126/science.270.5243.1811.
38. Hartley O, Offord RE. 2005. Engineering chemokines to develop optimized HIV inhibitors. Curr. Protein Pept. Sci. 6:207-219. http://dx.doi .org/10.2174/1389203054065400.
39. Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, Piatak M, Jr, Lifson JD, Salkowitz JR, Rodriguez B, Blauvelt A, Hartley O. 2004. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306:485-487. http://dx.doi.org/10 .1126/science.1099288.
40. Pastore C, Picchio GR, Galimi F, Fish R, Hartley O, Offord RE, Mosier DE. 2003. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob. Agents Chemother. 47:509-517. http://dx.doi.org/10.1128/AAC.47.2.509-517.2003.
41. Polo S, Nardese V, De Santis C, Arcelloni C, Paroni R, Sironi F, Verani A, Rizzi M, Bolognesi M, Lusso P. 2000. Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation. Eur. J. Immunol. 30:3190-3198. http://dx.doi.org/10 .1002/1521-4141(200011)30:11<3190::AID-IMMU3190>3.0.CO;2-E.
42. Vangelista L, Secchi M, Liu X, Bachi A, Jia L, Xu Q, Lusso P. 2010. Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers. Antimicrob. Agents Chemother. 54:2994-3001. http://dx.doi.org/10.1128/AAC.01492-09.
43. Secchi M, Xu Q, Lusso P, Vangelista L. 2009. The superior folding of a RANTES analogue expressed in lactobacilli as compared to mammalian cells reveals a promising system to screen new RANTES mutants. Protein Expr. Purif. 68:34-41. http://dx.doi.org/10.1016/j.pep.2009.06.018.
44. Langmead CJ, Christopoulos A. 2014. Functional and structural perspectives on allosteric modulation of GPCRs. Curr. Opin. Cell Biol. 27:94-101. http://dx.doi.org/10.1016/j.ceb.2013.11.007.
45. Duma L, Häussinger D, Rogowski M, Lusso P, Grzesiek S. 2007. Recognition of RANTES by extracellular parts of the CCR5 receptor. J. Mol. Biol. 365:1063-1075. http://dx.doi.org/10.1016/j.jmb.2006.10.040.
46. Colin P, Bénureau Y, Staropoli I, Wang Y, Gonzalez N, Alcami J, Hartley O, Brelot A, Arenzana-Seisdedos F, Lagane B. 2013. HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines. Proc. Natl. Acad. Sci. U. S. A. 110:9475-9480. http://dx.doi .org/10.1073/pnas.1222205110.
47. Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, Li T, Ma L, Fenalti G, Li J, Zhang W, Xie X, Yang H, Jiang H, Cherezov V, Liu H, Stevens RC, Zhao Q, Wu B. 2013. Structure of the CCR5 chemokine receptor- HIV entry inhibitor maraviroc complex. Science 341:1387-1390. http://dx .doi.org/10.1126/science.1241475.
48. Nedellec R, Coetzer M, Lederman MM, Offord RE, Hartley O, Mosier DE. 2010. "Resistance" to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 (HIV-1) SF162 or simian-human immunodeficiency virus (SHIV) SF162-p3 do not confer resistance. J. Virol. 84:5842-5845. http://dx.doi.org/10.1128/JVI.01907-09.
49. Nedellec R, Coetzer M, Lederman MM, Offord RE, Hartley O, Mosier DE. 2011. Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use. PLoS One 6:e22020. http://dx.doi.org/10.1371/journal.pone.0022020.